Analysis of apremilast for severe chronic plaque psoriasis, September 2023
Page last updated: 22 March 2024
Drug utilisation sub-committee (DUSC)
September 2023
Abstract
Purpose
To review the utilisation of apremilast for severe chronic plaque psoriasis (CPP) and a market review as requested by DUSC at its June 2023 meeting.
Date of listing on the Pharmaceutical Benefits Scheme (PBS)
Apremilast was PBS listed for CPP on 1 January 2021.
Data Source / methodology
Data extracted from the PBS database maintained by Department of Health and Aged Care, processed by Services Australia were used for the analyses.
Key Findings
- In 2022, 146,205 prescriptions for the treatment of CPP were supplied to 31,121 patients.
- In 2021, 128,318 prescriptions for the treatment of CPP were supplied to 27,864 patients.
- In 2022, 4,908 apremilast patients were supplied 25,248 prescriptions for the treatment of CPP.
- In 2021, 3,312 apremilast patients were supplied 14,311 prescriptions for the treatment of plaque psoriasis.
- Actual utilisation of apremilast for the CPP was different from estimated. The number of treated patients and prescriptions supplied were lower than estimated.
